Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The origin of stroma surrounding epithelial ovarian cancer cells.

Akahane T, Hirasawa A, Tsuda H, Kataoka F, Nishimura S, Tanaka H, Tominaga E, Nomura H, Chiyoda T, Iguchi Y, Yamagami W, Susumu N, Aoki D.

Int J Gynecol Pathol. 2013 Jan;32(1):26-30. doi: 10.1097/PGP.0b013e3182518533.

PMID:
23202778
2.

p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.

Laframboise S, Chapman W, McLaughlin J, Andrulis IL.

Cancer J. 2000 Sep-Oct;6(5):302-8.

PMID:
11079169
3.

Improved classification of epithelial ovarian cancer: results of 3 danish cohorts.

Steffensen KD, Waldstrøm M, Grove A, Lund B, Pallisgård N, Jakobsen A.

Int J Gynecol Cancer. 2011 Dec;21(9):1592-600. doi: 10.1097/IGC.0b013e31822a0f6b.

PMID:
21926912
4.

Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.

Peng DX, Luo M, Qiu LW, He YL, Wang XF.

Oncol Rep. 2012 Apr;27(4):1238-44. doi: 10.3892/or.2012.1625. Epub 2012 Jan 11.

5.

Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism.

Ma Z, Zhang T, Wang R, Cheng Z, Xu H, Li W, Wang Y, Wang X.

Int J Gynecol Cancer. 2011 May;21(4):616-24. doi: 10.1097/IGC.0b013e3182150e98.

PMID:
21543928
6.

p53 mutation is infrequent in clear cell carcinoma of the ovary.

Ho ES, Lai CR, Hsieh YT, Chen JT, Lin AJ, Hung MH, Liu FS.

Gynecol Oncol. 2001 Feb;80(2):189-93.

PMID:
11161858
7.

The role of p53 protein and MMP-2 tumor/stromal cells expression on progressive growth of ovarian neoplasms.

Grelewski PG, Bar JK.

Cancer Invest. 2013 Aug;31(7):472-9. doi: 10.3109/07357907.2013.820320.

PMID:
23915071
8.

Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.

Giordano G, Azzoni C, D'Adda T, Rocco A, Gnetti L, Froio E, Merisio C, Melpignano M.

Pathol Res Pract. 2008;204(3):163-74. doi: 10.1016/j.prp.2007.11.001. Epub 2008 Jan 3.

PMID:
18180113
9.

The level of RCAS1 expression is inversely correlated with the number of vimentin-positive stromal cells in epithelial ovarian cancer.

Sonoda K, Miyamoto S, Kobayashi H, Ogawa S, Okugawa K, Taniguchi S, Wake N.

Int J Gynecol Cancer. 2009 Jul;19(5):838-43. doi: 10.1111/IGC.0b013e3181a5ff6a.

PMID:
19574770
10.

Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.

Alvarez AA, Axelrod JR, Whitaker RS, Isner PD, Bentley RC, Dodge RK, Rodriguez GC.

Gynecol Oncol. 2001 Aug;82(2):273-8.

PMID:
11531279
11.
12.
13.

[Advances in origin and pathogenesis of epithelial ovarian cancer].

Liu CR, Zheng WX.

Zhonghua Bing Li Xue Za Zhi. 2011 Aug;40(8):569-72. Review. Chinese. No abstract available.

PMID:
22169654
14.

CD24, COX-2, and p53 in epithelial ovarian cancer and its clinical significance.

Zhu J, Zhang G, Lu H.

Front Biosci (Elite Ed). 2012 Jun 1;4:2745-51.

PMID:
22652675
15.

Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.

Bagnoli M, Balladore E, Luison E, Alberti P, Raspagliesi F, Marcomini B, Canevari S, Mezzanzanica D.

Mol Cancer Ther. 2007 Feb;6(2):762-72.

16.

A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.

Righetti SC, Della Torre G, Pilotti S, Ménard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Böhm S, Bresciani GL, Spatti G, Zunino F.

Cancer Res. 1996 Feb 15;56(4):689-93.

17.

BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.

Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD 2nd, Lanchbury JS, Krivak TC.

Gynecol Oncol. 2012 Jun;125(3):677-82. doi: 10.1016/j.ygyno.2012.03.006. Epub 2012 Mar 8.

PMID:
22406760
18.

p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.

Okuda T, Otsuka J, Sekizawa A, Saito H, Makino R, Kushima M, Farina A, Kuwano Y, Okai T.

Gynecol Oncol. 2003 Mar;88(3):318-25.

PMID:
12648581
19.

p53 gene analysis of ovarian borderline tumors and stage I carcinomas.

Kupryjanczyk J, Bell DA, Dimeo D, Beauchamp R, Thor AD, Yandell DW.

Hum Pathol. 1995 Apr;26(4):387-92.

PMID:
7705816
20.

p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study.

Tateyama H, Eimoto T, Tada T, Mizuno T, Inagaki H, Hata A, Sasaki M, Masaoka A.

Am J Clin Pathol. 1995 Oct;104(4):375-81.

PMID:
7572785

Supplemental Content

Support Center